Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.65 GBX | +0.45% | +0.60% | -46.99% |
Mar. 27 | Jefferies Downgrades Life Science REIT to Hold from Buy, Cuts PT | MT |
Mar. 27 | Sorted renews M&S deal; Tribe completes drill build | AN |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- With a P/E ratio at 10.81 for the current year and 8.17 for next year, earnings multiples are highly attractive compared with competitors.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Residential REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-46.99% | 148M | - | ||
+9.57% | 29.29B | A- | ||
+12.58% | 25.89B | B | ||
+3.64% | 21.65B | B- | ||
+9.39% | 17.55B | B+ | ||
+4.79% | 16.42B | B | ||
-10.85% | 14.96B | C | ||
+2.24% | 13.47B | B | ||
+6.69% | 13.43B | B | ||
-8.22% | 12.17B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LABS Stock
- Ratings Life Science REIT plc